ANNX Annexon, Inc. Insider Trading

Director Muneer Satter bought 613,497 shares of ANNX at $5.41, increasing holdings to 10.34M; his prior 5 ANNX buys all showed positive 90d returns.

Muneer Satter, a Director, purchased 613,497 shares of Annexon at $5.41 on 2026-05-28 for $3,319,018.77, expanding his holdings by 6.3% to 10.34M shares. His prior trades at ANNX demonstrate a strong pattern: all 5 previous buys exhibited positive 90-day returns, ranging from +13.0% to +63.6%, with a 90d win rate of 100% at this ticker. The current stock price of $5.42 sits 24.5% below its 52-week high of $7.18, suggesting this purchase occurred in a depressed valuation environment relative to recent trading levels. However, the company remains unprofitable with a net income of -$44.1M over its most recent full fiscal year, so the fundamental backdrop remains challenged despite the insider's continued accumulation pattern.

Director Carson William H. adds 8,000 shares to growing stake in money-losing biotech amid 52-week high pullback; repeat buyer with mixed near-term timing.

Carson William H., a director at Annexon, is making his sixth open-market purchase of the company's stock in 36 months, buying 8,000 additional shares while the stock trades notably below its 52-week high and amid a recent one-month decline. This purchase builds on a pattern of consistent accumulation at this ticker—he has been a repeat buyer with no sales—but his prior purchases at Annexon show mixed results: four of five prior acquisitions saw the stock gain within 30 days, though only two showed gains over a 90-day window, with three facing declines. More broadly, Carson has completed 18 open-market purchases across all his holdings over the past three years with no sales, suggesting a habitual buyer's stance, though the inconsistent returns on his Annexon purchases suggest his timing here has been uneven. The company itself is unprofitable, burning cash with losses in both the most recent quarter and full-year results, making this a bet on a struggling biotech rather than a financially stable operation. The combination of a director's continued commitment to accumulation at depressed prices, paired with a track record of mixed execution and a company in preclinical distress, presents a mixed signal: persistence of conviction mitigated by evidence of poor near-term market timing on prior Annexon buys.